Kardigan files for IPO to fund late‑stage cardiovascular pipeline

Kardigan, a Princeton, N.J.–based cardiovascular biotech, has filed for a U.S. IPO to fund the late‑stage development of three experimental heart medicines where no approved treatments currently exist.

The company is advancing danicamtiv (for genetic dilated cardiomyopathy), ataciguat (for calcific aortic valve stenosis), and tonlamarsen (for post‑hospitalization acute severe hypertension).

Kardigan filed its S‑1 with the SEC on May 26, 2026, declaring intentions to raise up to about $100 million and listing on Nasdaq under the ticker KARD, with J.P. Morgan, Jefferies, Leerink and TD Cowen as bookrunners.

Led by former MyoKardia executives, Kardigan has raised about $554 million in private capital to date and plans to use IPO proceeds plus its existing ~$287 million cash to advance all three late‑stage programs through clinical development and potential regulatory filings.